The Role of Antidepressants or Antipsychotics in Preventing Psychosis
NCT ID: NCT01724372
Last Updated: 2014-05-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2012-10-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Our primary hypotheses are that compared to aripiprazole, fluoxetine will be better tolerated and will lead to greater improvement in symptoms at the end of 6 months of treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fluoxetine vs Aripiprazole Comparative Trial (FACT)
NCT02357849
Aripiprazole Treatment of Prodromal Patients
NCT00237874
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
NCT00320671
Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole
NCT01155544
The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset
NCT06128408
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antidepressant
Fluoxetine
Antidepressant
Antipsychotic
Aripiprazole
Antipsychotic
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antidepressant
Antipsychotic
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to understand and speak English
* Have at least one sub-threshold positive psychotic symptom that is moderate, moderately severe, or severe
Exclusion Criteria
* Current psychosis
* Current diagnosis of Major Depressive Disorder, single episode or recurrent, severe without psychotic features
* Lifetime diagnosis of substance abuse or dependence (excluding nicotine)
* Current stimulant treatment
* Any significant medical condition that contra-indicates treatment with either aripiprazole or fluoxetine, including history of neurological, neuroendocrine or other medical condition known to affect the brain
* Estimated intelligence quotient \< 70
12 Years
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Zucker Hillside Hospital
OTHER
St. Luke's-Roosevelt Hospital Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-094
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.